# Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

> **NCT04583228** · PHASE1 · COMPLETED · sponsor: **Hengenix Biotech Inc** · enrollment: 32 (actual)

## Conditions studied

- COVID 19

## Interventions

- **DRUG:** HLX71
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04583228
- **Lead sponsor:** Hengenix Biotech Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-08
- **Primary completion:** 2021-07-15
- **Final completion:** 2021-07-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04583228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04583228, "Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04583228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*